Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 8, 2018 - The FDA approved a Warning and Precaution section to the Exondys 51 (eteplirsen) drug label regarding hypersensitivity reactions.
Download PDF
Return to publications
